LEADER 03041nam  22005655  450 
001 9910987788703321
005 20250708000247.0
010   $a981-9757-42-8
024 7 $a10.1007/978-981-97-5742-8
035   $a(CKB)37916648100041
035   $a(DE-He213)978-981-97-5742-8
035   $a(MiAaPQ)EBC31959371
035   $a(Au-PeEL)EBL31959371
035   $a(EXLCZ)9937916648100041
100   $a20250313d2025      u|         0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aPreclinical cancer models for translational research and drug development /$fedited by Suresh P.K., Arindam Banerjee
205   $a1st ed. 2025.
210  1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2025.
215   $a1 online resource (XI, 168 p. 51 illus., 50 illus. in color.)
311 08$a981-9757-41-X 
327   $aPreclinical Models for Cancer Research and Development.-Insight on the Current Advancements in the Diagnosis and Treatment of Head and Neck Cancer -- The role of oral cancer heterogeneity in therapies in various cellular and preclinical models -- In-depth analysis of Self-assembled in-vitro spheroidal and organoid systems -- Preclinical in vivo animal xenograft models -- Heterogeneity and biomarkers of therapeutic response and resistance -- Higher Order in vitro Models of dysregulated bioenergetics mechanisms and drug development -- In Silico Strategies for Cancer Model Development and Anticancer Drug Testing.
330   $aThis book provides updated information on certain in vitro and preclinical in vivo cancer models. The topics covered include an update on advancements in the diagnosis, treatment and heterogeneity in certain cancers; the development of preclinical in vitro and xenograft-based in vivo cancer models as well as their validation based on widely-accepted biomarkers; modelling of aberrations in bioenergetics in cancers. Also, the importance and latest advances of in silico modeling for the design of new and potent anti-cancer drugs has been reviewed. Cutting-edge and resourceful, this book is valuable for researchers, academicians, and professionals involved in cancer research.
606   $aCancer
606   $aCancer$xAnimal models
606   $aTumor markers
606   $aCancers
606   $aCancer Models
606   $aTumour Biomarkers
615  0$aCancer.
615  0$aCancer$xAnimal models.
615  0$aTumor markers.
615 14$aCancers.
615 24$aCancer Models.
615 24$aTumour Biomarkers.
676   $a571.978
676   $a616.994
702   $aP.K$b Suresh$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aBanerjee$b Arindam$4edt$4http://id.loc.gov/vocabulary/relators/edt
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910987788703321
996   $aPreclinical cancer models for translational research and drug development$94337474
997   $aUNINA